Earum Pharmaceuticals Ltd - 542724 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Saumil A Bhavnagari & PACs Earum Pharmaceuticals Ltd - 542724 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajesh Nanubhai Jhaveri HUF Earum Pharmaceuticals Ltd - 542724 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nimit Jayendrabhai Shah Earum Pharmaceuticals Ltd - 542724 - Closure of Trading Window
Intimation of Closure of Trading Window Earum Pharmaceuticals Ltd - 542724 - Intimation Of Trading Approval Received For Rights Issue Of Fully Paid-Up Equity Shares By Earum Pharmaceuticals Limited ('The Company') Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulations, 2015.
With reference to application made by the Company dated 25th January, 2023 regarding the proposed Rights issue of fully paid-up Equity shares by the Company. We would like to inform you that the Company has received the trading approval from BSE Limited for the Rights Issue of fully paid-up Equity shares. The approval letter received from the Stock Exchange i.e. BSE Limited is enclosed herewith. Earum Pharmaceuticals Ltd - 542724 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (LODR) Regulations, 2015 and Regulation 92 of the SEBI (ICDR) Regulations, 2018, the Company has given Newspaper Advertisement on 27th June, 2023 of Post Issue - Basis of Allotment for Rights Issue of 185432518 Equity shares at a price of Rs. 2/- Earum Pharmaceuticals Ltd - 542724 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Earum Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/07/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of the Company will be held on Friday, 14th July, 2023 at 11:00 A.M. at the Registered Office of the Company situated at A-1106, Empire Business Hub Near AUDA Water Tank, Science City Road, Sola, Ahmedabad - 380060, to discuss and consider inter alia: The proposal for Buyback of Equity Shares of the Company. The proposal to recommend the declaration of Final Dividend for the F.Y. 2022-23. The proposal of Issue of Bonus Equity Shares to the existing equity Shareholders of the Company. The proposal of sub-division of equity shares of the Company. To finalize the date, day, time and venue of Annual General Meeting of shareholders for the F.Y. 2022-23. Earum Pharmaceuticals Ltd - 542724 - Board Meeting Outcome for Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 (The 'Listing Regulations') - Outcome Of The Board Meeting
This is to inform that, the Board of Directors of the Company at its Meeting held today has: 1. Approved the proposal for opening of three overseas branch offices of the Company along with such other compliances or procedures necessary or applicable at countries mentioned below: DUBAI, UAE NIGERIA, WEST AFRICA REGION AND KENYA, EAST AFRICA REGION Kindly take the same on your record and oblige us. Earum Pharmaceuticals Ltd - 542724 - Submission Of Revised Audited Financial Results For The Quarter And Year Ended On 31St March, 2023 Along With Auditor'S Report And Declaration
In reference to captioned subject and pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Revised Audited Financial Results for the Quarter and Financial Year ended on 31st March, 2023 along with Auditor's Report and Declaration due to discrepancy financial result is not signed by the chairperson or managing director, or a whole-time director or in the absence of all, other authorized director. Further this is inform you that we were already submitted Audited Financial Results for the Quarter and Year ended on 31st March, 2023 as on 29th May 2023, for the ratify the discrepancy in Financial Result we are submitting this revised Result. There are no changes in Financial Result. Earum Pharmaceuticals Ltd - 542724 - Board Meeting Outcome for Rights Issue Committee Approves Allotment Of Shares W.R.T. Rights Issue Of The Company
1. Allotment of 18,54,32,518 (Eighteen Crores Fifty-Four Lakhs Thirty-Two Thousand Five Hundred and Eighteen) Equity Shares having face value of Rs. 2/- (Rupees Two Only) on a rights basis to the existing equity shareholders of the Company at a price of Rs. 2/- (Rupees Two Only) per equity share in the ratio of 4:1 i.e. 4 (Four) fully paid-up Equity shares for every 1 (One) Equity Share held by the eligible equity shareholders as on the record date i.e. Monday, 10th April, 2023. The said allotment is pursuant to the Letter of Offer dated 19th April, 2023 and finalisation of the Basis of Allotment as approved by BSE Limited ('BSE'), the Designated Stock Exchange.